Nephrocare Health Services Limited announced its unaudited standalone financial results for the quarter and half-year ended September 30, 2026. The company reported a standalone profit of ₹143.08 crore for the quarter and consolidated comprehensive income of ₹342.74 crore for the same period. The Board of Directors also approved the financial results and the limited review report from B S R and Co.
Nephrocare Health Services Announces Q2 FY27 Financial Results
Nephrocare Health Services Limited has officially disclosed its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company’s Board of Directors convened on November 3, 2026, to consider and approve these results.
Standalone Financial Highlights
For the quarter ended September 30, 2026, Nephrocare Health Services reported a standalone Profit / (loss) for the period/year of ₹143.08 crore. The standalone total comprehensive income / (loss) for the period/year stood at ₹140.61 crore.
Consolidated Financial Highlights
On a consolidated basis, the company announced a total comprehensive income / (loss) for the period/year of ₹342.74 crore for the quarter ended September 30, 2026. This figure includes the profit attributable to owners of the company and other comprehensive income.
Limited Review Report
The unaudited financial results were accompanied by a Limited Review Report issued by M/s. B S R and Co., Chartered Accountants. The report indicated that based on their review, nothing had come to their attention that caused them to believe that the accompanying statement was not prepared in accordance with the applicable accounting standards and regulations, or that it contained any material misstatement.
Key Financial Data Summary (Unaudited Standalone)
| Particulars | 30 September 2026 (Unaudited) | 30 June 2026 (Unaudited) | 30 September 2025 (Unaudited) |
|---|---|---|---|
| Revenue from operations | ₹1,765.79 crore | ₹1,703.78 crore | ₹1,559.20 crore |
| Profit / (loss) before tax | ₹169.11 crore | ₹166.93 crore | (₹306.17) crore |
| Profit / (loss) for the period/year | ₹143.08 crore | ₹125.63 crore | (₹324.14) crore |
| Total comprehensive income / (loss) for the period/year | ₹140.61 crore | ₹125.76 crore | (₹323.80) crore |
Key Financial Data Summary (Unaudited Consolidated)
| Particulars | 30 September 2026 (Unaudited) | 30 June 2026 (Unaudited) | 30 September 2025 (Unaudited) |
|---|---|---|---|
| Revenue from operations | ₹3,033.98 crore | ₹2,817.54 crore | ₹2,457.18 crore |
| Profit / (loss) before tax | ₹443.27 crore | ₹445.96 crore | (₹6.24) crore |
| Profit / (loss) for the period/year | ₹335.31 crore | ₹319.74 crore | (₹94.74) crore |
| Total comprehensive income / (loss) for the period/year | ₹342.74 crore | ₹330.52 crore | (₹10.84) crore |
Website Disclosure
A copy of this disclosure has been made available on the company’s official website, www.nephroplus.com, for public access.
Source: BSE
